Abstract:Alzheimer's disease (AD) is a progressive neurological disorder that affects the central nervous system (CNS), leading to memory and cognitive decline. In AD, the brain experiences three main structural changes: a significant decrease in the quantity of neurons, the development of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein, and the formation of amyloid beta (Aβ) or senile plaques, which are protein deposits found outside cells and surrounded by dystrophic neurites. Genetic studies have identified four genes associated with autosomal dominant or familial early-onset AD (FAD): amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2), and apolipoprotein E (ApoE). The formation of plaques primarily involves the accumulation of Aβ, which can be influenced by mutations in APP, PS1, PS2, or ApoE genes. Mutations in the APP and presenilin (PS) proteins can cause an increased amyloid β peptides production, especially the further form of amyloidogenic known as Aβ42. Apart from genetic factors, environmental factors such as cytokines and neurotoxins may also have a significant impact on the development and progression of AD by influencing the formation of amyloid plaques and intracellular tangles. Exploring the causes and implications of protein aggregation in the brain could lead to innovative therapeutic approaches. Some promising therapy strategies that have reached the clinical stage include using acetylcholinesterase inhibitors, estrogen, nonsteroidal anti-inflammatory drugs (NSAIDs), antioxidants, and antiapoptotic agents. The most hopeful therapeutic strategies involve inhibiting activity of secretase and preventing the β-amyloid oligomers and fibrils formation, which are associated with the β-amyloid fibrils accumulation in AD. Additionally, immunotherapy development holds promise as a progressive therapeutic approach for treatment of AD. Recently, the two primary categories of brain stimulation techniques that have been studied for the treatment of AD are invasive brain stimulation (IBS) and non-invasive brain stimulation (NIBS). In this article, the amyloid proteins that play a significant role in the AD formation, the mechanism of disease formation as well as new drugs utilized to treat of AD will be reviewed.

Alzheimer's Disease: an Axonal Injury Disease?

Alzheimer’s Disease: an Axonal Injury Disease?

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis

Advances in the Pathogenesis of Alzheimer's Disease: a Re-Evaluation of Amyloid Cascade Hypothesis.

Pathological Axonal Enlargement in Connection with Amyloidosis, Lysosome Destabilization and Hemorrhage is a Major Defect in the Alzheimer’s Disease

Mechanisms of Alzheimer’s Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors

Sequence of Molecular Events in the Development of Alzheimer's Disease: Cascade Interactions from Beta-Amyloid to Other Involved Proteins

Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments

Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy.

Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses

Alzheimer's disease.

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Pathological axonal enlargement in connection with amyloidosis, lysosome destabilization and hemorrhage is a major defect in Alzheimer's disease

Transient Focal Cerebral Ischemia/Reperfusion Induces Early and Chronic Axonal Changes in Rats: Its Importance for the Risk of Alzheimer'S Disease

Mechanism of axonal transport dysfuction of mitochondria in Alzheimer's disease

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease

α-synuclein in the pathophysiology of Alzheimer’s disease